Azetidinyl-acetamides as CXCR7 inhibitors

A compound having formula (I):

• or a pharmaceutically acceptable salt, hydrate, N-oxide, isotopically enriched or enantiomerically enriched version or a rotamer thereof, wherein
• HAr is a five-membered heteroaryl ring;
• Ar1 is selected from the group consisting of phenyl, pyridyl, pyrimidinyl, and pyrazinyl;
• Ar2 is aryl or heteroaryl, each of which is independently monocyclic or fused-bicyclic;
• the subscript m is 0, 1 or 2;
• the subscript n is 0, 1, 2 or 3;
• the subscript p is 0, 1, 2 or 3;
• the subscript q is 0, 1, 2, 3 or 4;
• each R1 is a member independently selected from the group consisting of halogen, CN, C1-4 alkyl, C1-4 haloalkyl, —NRaRb, —ORa, —CO2Ra, and —C(O)NRaRb;
• each R2 is a member independently selected from the group consisting of halogen, CN, C1-4 alkyl, C1-4 haloalkyl, —NRaRb, —ORa, —CO2Ra, and —C(O)NRaRb;
• each R3 is a member selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, —CO2Ra, —X—CO2Ra, —C(O)NRaRb and —X—C(O)NRaRb;
• each of R4a and R5a, is a member independently selected from the group consisting of H, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, —X—ORa, —CO2Ra, —X—CO2Ra, —X—NRaRb, —C(O)NRaRb and —X—C(O)NRaRb,
• each of R4 and R5, is a member independently selected from the group consisting of H, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, —X—ORa, —CO2Ra, —X—CO2Ra, —X—NRaRb, —C(O)NRaRb and —X—C(O)NRaRb;
• or R4 and R5 are combined to form a three- to five-membered ring having 0 or 1 heteroatom ring vertex selected from O, S or N, wherein said three- to five-membered ring is unsubstituted or substituted with 1-4 substituents independently selected from the group consisting of halogen, CN, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy;
• each R6 is a member independently selected from the group consisting of halogen, CN, —X—CN, C1-4 alkyl, C1-4 haloalkyl, C3-6 cycloalkyl, C1-4 hydroxyalkyl, —ORa, —CO2Ra, —X—CO2Ra, —NRaRb, —X—NRaRb, —C(O)NRaRb, and —X—C(O)NRaRb,
• R7 is a member selected from the group consisting of C1-8 alkyl, C3-8 hydroxyalkyl, C1-4 alkoxy-C2-4 alkyl, —C(O)NH—C1-8 alkyl, —C(O)—C1-8 alkyl, —S(O)2—C1-8 alkyl, C3-8 cycloalkyl, —X—C3-8 cycloalkyl, C6-9 spirocycloalkyl, —X—C6-9 spirocycloalkyl, 4- to 7-membered heterocycloalkyl, —X-4- to 7-membered heterocycloalkyl, 7- to 11-membered spiroheterocycloalkyl, and —X-7- to 11-membered spiroheterocycloalkyl, wherein each R7 is substituted with zero to four substituents independently selected from the group consisting of hydroxy, methyl, ethyl, hydroxymethyl, fluoro, chloro, methoxy, ethoxy and cyclopropyl;
• each Ra and Rb is independently selected from the group consisting of H, C1-4 alkyl, C1-4 haloalkyl, C3-6 cycloalkyl, and C3-6 cycloalkyl-C1-4 alkyl;
• each X is a C1-4 alkylene linking group wherein any of the methylene portions of X are unsubstituted or substituted with one or two methyl groups.